The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide

Chun Chun Yang, Jiunn Diann Lin, Ko Lin Kuo, Chung Ze Wu, Jer Chuan Li, Yi Jen Hung, Tso Fu Wang, Chien Hsing Lee, Shi Wen Kuo, Dee Pei

研究成果: 雜誌貢獻文章同行評審

4 引文 斯高帕斯(Scopus)


Aims: Sulfonylurea with long half-life such as gliclazide has sustained stimulation on insulin secretion compared to repaglinide which has short half-life for only about 1 h. In this hospital cohort, randomized, cross-over study, we used modified low dose graded glucose infusion test (M-LDGGI) to evaluate second phase insulin secretion after 4 months of treatment with either gliclazide or repaglinide. Methods: Sixteen fresh type 2 diabetes with age of 49.5 ± 2.6 years old and BMI of 25.3 ± 0.9 kg/m2 were included. After titration and maintain dose stage, all cases were randomized to the repaglinide or gliclazide treatment for 4 months. At the end of each treatment period, an M-LDGGI was done. Results: The general linear model repeated measurement was used to evaluate the plasma glucose, insulin and insulin/glucose curve during M-LDGGI. Although the plasma insulin and insulin/glucose ratios were higher at 40 min and 100-120 min, they did not reach statistically significant. The area under curve of the plasma glucose, insulin and insulin/glucose ratio was also used to evaluate the secretory capacity of beta cell. Although the AUC of the ratio of plasma insulin/plasma glucose seems to be more evident than the curves, they are still not significantly different with each other. Conclusions: In conclusion, although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months. Further study with longer duration and larger study cohort are needed to solve this interesting and important question.

頁(從 - 到)37-42
期刊Diabetes and Metabolic Syndrome: Clinical Research and Reviews
出版狀態已發佈 - 2月 2007

ASJC Scopus subject areas

  • 內分泌學、糖尿病和代謝
  • 內科學


深入研究「The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide」主題。共同形成了獨特的指紋。